About Hologic (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Industry, Sector and Symbol
Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:HOLX
CUSIP43644010
Phone508-263-2900
Debt
Debt-to-Equity Ratio0.87%
Current Ratio1.25%
Quick Ratio0.98%
Price-To-Earnings
Trailing P/E Ratio18.87
Forward P/E Ratio17.02
P/E Growth1.73
Sales & Book Value
Annual Sales$3.06 billion
Price / Sales3.46
Cash Flow$3.6651 per share
Price / Cash10.45
Book Value$9.93 per share
Price / Book3.86
Profitability
EPS (Most Recent Fiscal Year)$2.03
Net Income$755.50 million
Net Margins34.53%
Return on Equity20.07%
Return on Assets7.11%
Miscellaneous
Employees6,233
Outstanding Shares276,530,000
Hologic (NASDAQ:HOLX) Frequently Asked Questions
What is Hologic's stock symbol?
Hologic trades on the NASDAQ under the ticker symbol "HOLX."
How were Hologic's earnings last quarter?
Hologic (NASDAQ:HOLX) issued its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.05. The medical equipment provider earned $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The company's revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.52 EPS. View Hologic's Earnings History.
When is Hologic's next earnings date?
What guidance has Hologic issued on next quarter's earnings?
Hologic issued an update on its second quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $0.53-0.54 for the period, compared to the Thomson Reuters consensus estimate of $0.55. The company issued revenue guidance of $770-785, compared to the consensus revenue estimate of $790.90 million.
What price target have analysts set for HOLX?
13 Wall Street analysts have issued 1 year target prices for Hologic's stock. Their predictions range from $42.00 to $52.00. On average, they expect Hologic's share price to reach $47.5385 in the next twelve months. View Analyst Ratings for Hologic.
What are Wall Street analysts saying about Hologic stock?
Here are some recent quotes from research analysts about Hologic stock:
- 1. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming the broader industry. The company's blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover, growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (3/6/2018)
- 2. Needham & Company LLC analysts commented, "HOLX’s F1Q18 revenue was consistent with its 1/8/18 preannouncement while its EPS beat consensus. Management reiterated its FY18 revenue guidance and raised its EPS guidance due to tax reform. We note that HOLX expects to reinvest about half of its tax savings in marketing campaigns and R&D. HOLX’s organic revenue growth increased to 4.9% (adjusted for selling days) in F1Q18 from 4.4% in F4Q17. Breast Health growth improved from last quarter driven by the stronger international sales while Diagnostics growth (excluding the Blood divestiture) slowed. We expect HOLX’s revenue growth to accelerate as its Aesthetics business returns to Y/Y growth and it faces easier comps and we reiterate our Buy rating." (2/9/2018)
Who are some of Hologic's key competitors?
Some companies that are related to Hologic include Mylan (MYL), Sunny Optical Technology (Group) (SNPTF), Align Technology (ALGN), AmerisourceBergen (ABC), Cardinal Health (CAH), Centene (CNC), Cerner (CERN), Eisai (ESALY), Lonza Group (LZAGY), Teva Pharmaceutical Industries (TEVA), Sino Biopharmaceut (SBMFF), Idexx Laboratories (IDXX), Coloplast (CLPBY), Laboratory Corp. of America (LH), Smith & Nephew (SNN), UCB (UCBJF), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).
Who are Hologic's key executives?
Hologic's management team includes the folowing people:
- Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer (Age 54)
- Robert W. McMahon, Chief Financial Officer (Age 49)
- Peter J. Valenti III, Division President- Breast and Skeletal Health (Age 54)
- Thomas A. West, Division President- Diagnostics (Age 53)
- Allison P. Bebo, Senior Vice President - Human Resources (Age 49)
- Michael J. Watts, Vice President, IR Contact Officer
- John M. Griffin, General Counsel (Age 57)
- Sally W. Crawford, Lead Independent Director (Age 64)
- Charles J. Dockendorff, Director (Age 63)
- Namal Nawana, Director (Age 47)
Has Hologic been receiving favorable news coverage?
News stories about HOLX stock have trended positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hologic earned a news sentiment score of 0.44 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Hologic?
Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hologic's stock price today?
One share of HOLX stock can currently be purchased for approximately $38.30.
How big of a company is Hologic?
Hologic has a market capitalization of $10.59 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.
How can I contact Hologic?
Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]
MarketBeat Community Rating for Hologic (HOLX)
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hologic (NASDAQ:HOLX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Hologic in the last 12 months. Their average twelve-month price target is $47.5385, suggesting that the stock has a possible upside of 24.12%. The high price target for HOLX is $52.00 and the low price target for HOLX is $42.00. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.69 | 2.79 | 2.86 | 2.69 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $47.5385 | $48.3571 | $48.7857 | $47.7692 |
| Price Target Upside: | 24.12% upside | 28.10% upside | 11.26% upside | 29.49% upside |
Hologic (NASDAQ:HOLX) Consensus Price Target History
Hologic (NASDAQ:HOLX) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Hologic (NASDAQ:HOLX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 97.51%
Hologic (NASDAQ HOLX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Allison P. Bebo | SVP | Sell | 7,000 | $38.75 | $271,250.00 | |  |
| 3/15/2018 | Charles J Dockendorff | Director | Buy | 13,000 | $38.80 | $504,400.00 | | |
| 2/13/2018 | Namal Nawana | Director | Buy | 6,600 | $37.88 | $250,008.00 | 6,954 | |
| 11/20/2017 | Karleen Marie Oberton | VP | Sell | 1,023 | $39.84 | $40,756.32 | | |
| 11/13/2017 | Elaine Ullian | Director | Sell | 9,282 | $40.50 | $375,921.00 | | |
| 11/8/2017 | Karleen Marie Oberton | VP | Sell | 1,256 | $39.29 | $49,348.24 | 9,406 | |
| 11/6/2017 | Karleen Marie Oberton | VP | Sell | 538 | $39.40 | $21,197.20 | 8,343 | |
| 10/10/2017 | Lawrence M Levy | Director | Sell | 9,596 | $36.81 | $353,228.76 | | |
| 10/9/2017 | Lawrence M Levy | Director | Sell | 7,138 | $37.38 | $266,818.44 | | |
| 9/7/2017 | Lawrence M. Levy | Director | Sell | 7,139 | $39.04 | $278,706.56 | | |
| 8/3/2017 | Elaine Ullian | Director | Sell | 6,902 | $40.12 | $276,908.24 | 23,810 | |
| 7/17/2017 | Karleen Marie Oberton | VP | Sell | 4,704 | $45.19 | $212,573.76 | | |
| 7/3/2017 | Elaine Ullian | Director | Sell | 8,849 | $45.28 | $400,682.72 | 23,810 | |
| 6/7/2017 | Lawrence M Levy | Director | Sell | 2,960 | $44.54 | $131,838.40 | 45,634 | |
| 6/2/2017 | Elaine Ullian | Director | Sell | 8,938 | $43.99 | $393,182.62 | 23,810 | |
| 5/30/2017 | Peter J Valenti III | Insider | Sell | 10,005 | $43.44 | $434,617.20 | 20,994 | |
| 5/24/2017 | Lawrence M Levy | Director | Sell | 9,193 | $42.93 | $394,655.49 | 46,206 | |
| 5/17/2017 | Lawrence M Levy | Director | Sell | 9,076 | $42.80 | $388,452.80 | 43,165 | |
| 5/10/2017 | Lawrence M Levy | Director | Sell | 9,837 | $45.34 | $446,009.58 | 40,577 | |
| 5/3/2017 | Lawrence M Levy | Director | Sell | 10,203 | $45.00 | $459,135.00 | 38,832 | |
| 4/26/2017 | Lawrence M Levy | Director | Sell | 10,374 | $44.46 | $461,228.04 | 37,377 | |
| 4/24/2017 | Sally Crawford | Director | Sell | 16,969 | $44.00 | $746,636.00 | 157,305 | |
| 4/19/2017 | Lawrence M Levy | Director | Sell | 10,836 | $42.49 | $460,421.64 | 25,839 | |
| 4/12/2017 | Lawrence M Levy | Director | Sell | 10,757 | $42.45 | $456,634.65 | 24,596 | |
| 4/3/2017 | Elaine Ullian | Director | Sell | 9,104 | $42.40 | $386,009.60 | 23,810 | |
| 3/8/2017 | Sally Crawford | Director | Sell | 17,396 | $42.00 | $730,632.00 | 152,305 | |
| 2/3/2017 | Elaine Ullian | Director | Sell | 9,423 | $39.54 | $372,585.42 | 36,798 | |
| 11/21/2016 | Karleen Marie Oberton | VP | Sell | 3,023 | $38.32 | $115,841.36 | 13,260 | |
| 11/15/2016 | Karleen Marie Oberton | VP | Sell | 1,211 | $36.55 | $44,262.05 | 10,859 | |
| 11/8/2016 | Karleen Marie Oberton | VP | Sell | 984 | $38.57 | $37,952.88 | 9,065 | |
| 11/7/2016 | Karleen Marie Oberton | VP | Sell | 522 | $38.53 | $20,112.66 | 9,839 | |
| 10/10/2016 | Elaine Ullian | Director | Sell | 18,236 | $39.88 | $727,251.68 | 42,898 | |
| 10/10/2016 | Karleen Marie Oberton | VP | Sell | 31,470 | $40.00 | $1,258,800.00 | 17,005 | |
| 7/21/2016 | Nancy Leaming | Director | Sell | 8,179 | $37.00 | $302,623.00 | 67,140 | |
| 7/11/2016 | Nancy Leaming | Director | Sell | 6,221 | $36.04 | $224,204.84 | 55,053 | |
| 6/1/2016 | Lawrence M Levy | Director | Sell | 17,794 | $34.41 | $612,291.54 | 23,257 | |
| 5/27/2016 | Peter J Valenti III | Insider | Sell | 10,022 | $33.83 | $339,044.26 | 9,023 | |
| 5/26/2016 | Elaine Ullian | Director | Sell | 6,896 | $33.85 | $233,429.60 | 31,157 | |
| 5/26/2016 | Karleen Marie Oberton | VP | Sell | 4,228 | $33.85 | $143,117.80 | 8,819 | |
| 2/24/2016 | David R Lavance Jr | Director | Sell | 11,621 | $34.50 | $400,924.50 | 20,983 | |
| 11/10/2015 | Lawrence M. Levy | Director | Sell | 20,000 | $40.70 | $814,000.00 | 3,914 | |
| 9/21/2015 | Lawrence M. Levy | Director | Sell | 5,000 | $42.02 | $210,100.00 | 3,914 | |
| 9/8/2015 | Wayne Wilson | Director | Sell | 100,000 | $39.00 | $3,900,000.00 | 39,215 | |
| 8/28/2015 | Wayne Wilson | Director | Sell | 11,146 | $39.70 | $442,496.20 | 39,215 | |
| 8/26/2015 | Wayne Wilson | Director | Sell | 25,080 | $38.61 | $968,338.80 | 39,215 | |
| 8/14/2015 | Wayne Wilson | Director | Sell | 13,257 | $42.20 | $559,445.40 | | |
| 6/3/2015 | Lawrence M Levy | Director | Sell | 10,000 | $36.45 | $364,500.00 | | |
| 5/22/2015 | Lawrence M Levy | Director | Sell | 5,000 | $35.05 | $175,250.00 | | |
| 5/4/2015 | Lawrence M Levy | Director | Sell | 10,000 | $34.36 | $343,600.00 | | |
| 3/6/2015 | David R Lavance Jr | Director | Sell | 12,000 | $32.12 | $385,440.00 | | |
| 2/13/2015 | David R Lavance Jr | Director | Sell | 8,000 | $30.32 | $242,560.00 | | |
| 1/29/2015 | Karleen Marie Oberton | VP | Sell | 18,997 | $30.00 | $569,910.00 | | |
| 11/11/2014 | Karleen Marie Oberton | VP | Sell | 2,609 | $26.30 | $68,616.70 | | |
| 11/3/2014 | Karleen Marie Oberton | VP | Sell | 12,507 | $26.83 | $335,562.81 | | |
| 10/31/2014 | Roger D Mills | SVP | Sell | 14,506 | $26.00 | $377,156.00 | | |
| 9/9/2014 | Elaine Ullian | Director | Buy | 7,900 | $25.36 | $200,344.00 | | |
| 5/9/2014 | Rohan Hastie | SVP | Sell | 6,037 | $24.36 | $147,061.32 | 1,500 | |
| 5/8/2014 | Glenn Muir | CFO | Sell | 50,000 | $24.26 | $1,213,000.00 | 815,306 | |
| 5/6/2014 | Glenn Muir | CFO | Sell | 196,000 | $23.29 | $4,564,840.00 | 815,306 | |
| 5/6/2014 | Lawrence Levy | Director | Sell | 5,052 | $23.58 | $119,126.16 | | |
| 5/6/2014 | Robert Lavallee | CAO | Sell | 22,796 | $23.58 | $537,529.68 | 11,341 | |
| 3/14/2014 | David Lavance, Jr. | Director | Sell | 5,500 | $21.49 | $118,195.00 | 122 | |
| 3/14/2014 | Glenn Muir | CFO | Sell | 160,000 | $21.51 | $3,441,600.00 | 815,306 | |
| 3/7/2014 | Mark Casey | CAO | Sell | 3,251 | $22.53 | $73,245.03 | 14,470 | |
| 2/11/2014 | Stephen Macmillan | CEO | Buy | 38,600 | $21.58 | $832,988.00 | 237,500 | |
| 2/7/2014 | Stephen Macmillan | CEO | Buy | 198,900 | $20.78 | $4,133,142.00 | 198,900 | |
| 12/13/2013 | Robert Lavallee | CAO | Sell | 15,677 | $21.70 | $340,190.90 | 11,341 | |
| 10/30/2013 | Glenn P Muir | CFO | Sell | 140,000 | $22.32 | $3,124,800.00 | | |
| 10/15/2013 | Glenn P Muir | CFO | Sell | 28,000 | $22.12 | $619,360.00 | | |
| 9/16/2013 | Glenn Muir | CFO | Sell | 28,000 | $20.45 | $572,600.00 | 825,891 | |
| 9/13/2013 | Robert Lavallee | CAO | Sell | 2,500 | $20.33 | $50,825.00 | 19,090 | |
| 8/20/2013 | David Brady | SVP | Sell | 42,328 | $22.80 | $965,078.40 | 27,749 | |
| 8/15/2013 | Glenn Muir | CFO | Sell | 28,000 | $22.49 | $629,720.00 | 825,891 | |
| 8/8/2013 | Lawrence Levy | Director | Sell | 5,000 | $22.50 | $112,500.00 | 5,052 | |
| 8/8/2013 | Mark Casey | CAO | Sell | 14,804 | $22.57 | $334,126.28 | 20,632 | |
| 7/19/2013 | Robert H Lavallee | CAO | Sell | 11,254 | $20.89 | $235,096.06 | | |
| 7/15/2013 | Glenn P Muir | CFO | Sell | 28,000 | $19.78 | $553,840.00 | | |
| 7/1/2013 | Robert Cascella | CEO | Sell | 20,000 | $19.55 | $391,000.00 | | |
| 6/17/2013 | Glenn P Muir | CFO | Sell | 28,000 | $21.42 | $599,760.00 | | |
| 6/3/2013 | Robert Cascella | CEO | Sell | 20,000 | $20.71 | $414,200.00 | | |
| 2/25/2013 | Lawrence M Levy | Director | Sell | 5,000 | $22.00 | $110,000.00 | | |
| 9/5/2012 | Glenn P Muir | CFO | Sell | 68,750 | $19.96 | $1,372,250.00 | | |
| 8/8/2012 | Glenn P Muir | CFO | Sell | 68,750 | $19.69 | $1,353,687.50 | | |
(Data available from 1/1/2013 forward)
Hologic (NASDAQ HOLX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Contrasting Check Cap (CHEK) & Hologic (HOLX)
www.americanbankingnews.com - April 20 at 9:22 PM |
 | Why Erin Andrews Wants Women To Start Talking About The "C-Word"
www.forbes.com - April 20 at 8:57 AM |
| Hologic (HOLX) Expected to Announce Quarterly Sales of $780.06 Million
www.americanbankingnews.com - April 20 at 2:34 AM |
 | Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea ...
www.prnewswire.com - April 19 at 5:11 PM |
 | Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea Rates than Those Treated with Minerva
finance.yahoo.com - April 19 at 5:11 PM |
| Traders Buy Large Volume of Call Options on Hologic (HOLX)
www.americanbankingnews.com - April 19 at 8:32 AM |
| Check Cap (CHEK) & Hologic (HOLX) Critical Review
www.americanbankingnews.com - April 18 at 11:08 PM |
| 4 MedTech Stocks to Keep in Good Books This Earnings Season
finance.yahoo.com - April 18 at 5:17 PM |
| Reviewing Check Cap (CHEK) & Hologic (HOLX)
www.americanbankingnews.com - April 18 at 3:26 PM |
| $0.53 Earnings Per Share Expected for Hologic (HOLX) This Quarter
www.americanbankingnews.com - April 18 at 3:08 PM |
| Hologic (HOLX) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 10:05 AM |
 | Goldman Remains Positive on Hologic (HOLX)
www.streetinsider.com - April 18 at 8:50 AM |
| Hologic (HOLX) PT Set at $43.00 by Goldman Sachs
www.americanbankingnews.com - April 18 at 8:37 AM |
| BidaskClub Lowers Hologic (HOLX) to Buy
www.americanbankingnews.com - April 16 at 9:49 AM |
| Check Cap (CHEK) vs. Hologic (HOLX) Critical Analysis
www.americanbankingnews.com - April 15 at 3:25 AM |
| Hologic (HOLX) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM |
| Hologic (HOLX) Price Target Cut to $45.00
www.americanbankingnews.com - April 13 at 7:51 PM |
| Hologic (HOLX) Price Target Cut to $49.00
www.americanbankingnews.com - April 13 at 3:16 PM |
| Hologic's (HOLX) Sector Perform Rating Reaffirmed at Royal Bank of Canada
www.americanbankingnews.com - April 12 at 3:58 PM |
| Hologic (HOLX) Earns "Equal Weight" Rating from Barclays
www.americanbankingnews.com - April 12 at 3:27 PM |
| Edited Transcript of HOLX presentation 6-Mar-17 9:35pm GMT
finance.yahoo.com - April 12 at 9:29 AM |
| Hologic (HOLX) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 9:30 PM |
| Reviewing Hologic (HOLX) & Check Cap (CHEK)
www.americanbankingnews.com - April 10 at 1:41 AM |
 | Hologic Looks Iffy For Now
seekingalpha.com - April 8 at 5:24 PM |
| Financial Comparison: Check Cap (CHEK) vs. Hologic (HOLX)
www.americanbankingnews.com - April 7 at 11:15 PM |
| Analyzing Hologic (HOLX) & Check Cap (CHEK)
www.americanbankingnews.com - April 7 at 12:18 AM |
| Wall Street Largely Bullish on Hologic Stock in March
finance.yahoo.com - April 4 at 3:47 PM |
| Can HOLX Stock Rebound from Its Recent Lows?
finance.yahoo.com - April 4 at 3:47 PM |
| Hologic’s Viera Expected to Be Key Growth Driver for 2018
finance.yahoo.com - April 4 at 8:52 AM |
| Hologic and Dexalytics Partner to Develop Software for Athletes
finance.yahoo.com - April 4 at 8:52 AM |
| Hologic to Announce Financial Results for the Second Quarter of Fiscal 2018 on Wednesday, May 2, 2018
www.prnewswire.com - April 3 at 5:03 PM |
| Hologic (HOLX) Expected to Post Quarterly Sales of $780.06 Million
www.americanbankingnews.com - April 3 at 3:21 AM |
| Brokerages Anticipate Hologic (HOLX) to Announce $0.53 EPS
www.americanbankingnews.com - April 1 at 3:17 PM |
| Hologic (HOLX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 1 at 8:16 AM |
| Hologic (HOLX) vs. Essilor International (ESLOY) Critical Contrast
www.americanbankingnews.com - March 31 at 9:10 AM |
| Evercore ISI Initiates Coverage on Hologic (HOLX)
www.americanbankingnews.com - March 30 at 11:43 PM |
| Hologic (HOLX) Upgraded by Bank of America to "Buy"
www.americanbankingnews.com - March 30 at 5:08 PM |
| Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod
finance.yahoo.com - March 29 at 9:02 AM |
| Hologic Forecasted to Earn FY2020 Earnings of $2.89 Per Share (HOLX)
www.americanbankingnews.com - March 29 at 8:46 AM |
 | Hologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod
www.zacks.com - March 28 at 4:56 PM |
| Piper Jaffray Remains Bullish on Hologic (HOLX)
www.streetinsider.com - March 28 at 9:03 AM |
| Hologic (HOLX) Reports FDA Approval of New Innovations on its 3Dimensions Mammography System
www.streetinsider.com - March 27 at 9:07 AM |
| FDA Approves New Innovations on Hologic's 3Dimensions™ Mammography System, the Fastest, Highest Resolution Breast Tomosynthesis System Ever(1)
www.prnewswire.com - March 27 at 8:12 AM |
| Hologic (HOLX) Lowered to Buy at Goldman Sachs
www.americanbankingnews.com - March 26 at 9:15 AM |
| Should Value Investors Consider Hologic (HOLX) Stock Now?
finance.yahoo.com - March 23 at 5:10 PM |
| Insider Selling: Hologic, Inc. (HOLX) SVP Sells 7,000 Shares of Stock
www.americanbankingnews.com - March 20 at 7:50 PM |
| Hologic, Inc. (HOLX) Expected to Earn Q1 2019 Earnings of $0.60 Per Share
www.americanbankingnews.com - March 20 at 11:12 AM |
| $779.91 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - March 17 at 4:46 AM |
| Hologic, Inc. (HOLX) Director Acquires $504,400.00 in Stock
www.americanbankingnews.com - March 16 at 7:52 PM |
 | Commit To Purchase Hologic At $30, Earn 5.8% Using Options - Nasdaq
www.nasdaq.com - March 16 at 6:01 PM |
Hologic (NASDAQ:HOLX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement
Hologic (NASDAQ HOLX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
